Amneal, Sun Pharma, Upsher-Smith and Wockhardt agreed to pay a combined $1.54 million to settle allegations that they illegally prevented market entry of a generic version of the Alzheimer's disease drug Namenda.
Drugmakers to pay $1.54M to settle pay-for-delay lawsuit
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.